Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Radiology

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1148/radiol.10091131PMID 20663970
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Collagenolytic Activity Is Suppressed in Organ-Cultured Human Skin Exposed to a Gadolinium-Based MRI Contrast Agent

  2010cited by this paper
• NSF after Gadovist exposure: a case report and hypothesis of NSF development.

  2009cited by this paper
• Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts

  2009cited by this paper
• Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.

  2009cited by this paper
• Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.

  2009cited by this paper
• Mechanism of NSF: New evidence challenging the prevailing theory

  2009cited by this paper
• Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure

  2008cited by this paper
• High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent

  2008cited by this paper
• Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

  2008cited by this paper
• Clinical and histological findings in nephrogenic systemic fibrosis.

  2008cited by this paper
• Extracellular gadolinium contrast agents: differences in stability.

  2008cited by this paper
• Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C

  2008cited by this paper
• Incidence of nephrogenic systemic fibrosis at two large medical centers.

  2008cited by this paper
• Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.

  2008cited by this paper
• Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis

  2008cited by this paper
• Imatinib mesylate treatment of nephrogenic systemic fibrosis.

  2008cited by this paper
• Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.

  2008cited by this paper
• Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.

  2008cited by this paper
• Case-control study of gadodiamide-related nephrogenic systemic fibrosis.

  2007cited by this paper
• Nephrogenic systemic fibrosis: risk factors and incidence estimation.

  2007cited by this paper
• Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum

  2007cited by this paper
• Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis.

  2007cited by this paper
• Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium.

  2007cited by this paper
• Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

  2007cited by this paper
• Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.

  2007cited by this paper
• Gadolinium deposition in nephrogenic fibrosing dermopathy.

  2007cited by this paper
• Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.

  2007cited by this paper
• MR contrast agents: Physical and pharmacologic basics

  2007cited by this paper
• Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

  2007cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)

  2006cited by this paper
• Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions.

  2006cited by this paper
• Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

  2006cited by this paper
• Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

  2006cited by this paper
• Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

  2004cited by this paper
• Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis

  2004cited by this paper
• Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin.

  2004cited by this paper
• Nephrogenic fibrosing dermopathy with systemic involvement.

  2003cited by this paper
• Hyperphosphataemia in renal failure: causes, consequences and current management.

  2003cited by this paper
• Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.

  1998cited by this paper

• Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role

  2025cites this paper
• Pr3+ Visible to Ultraviolet Upconversion for Antimicrobial Applications

  2025cites this paper
• Copper pyrazole complexes as potential anticancer agents: Evaluation of cytotoxic response against cancer cells and their mechanistic action at the molecular level

  2024cites this paper
• Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses

  2023cites this paper
• American Society of Regional Anesthesia and Pain Medicine contrast shortage position statement

  2022cites this paper
• Toxicity of rare earth elements: An overview on human health impact

  2022cites this paper
• Propidium uptake and ATP release in A549 cells share similar transport mechanisms.

  2022cites this paper
• The Use of Contrast Agents in Interventional Pain Procedures: A Multispecialty and Multisociety Practice Advisory on Nephrogenic Systemic Fibrosis, Gadolinium Deposition in the Brain, Encephalopathy After Unintentional Intrathecal Gadolinium Injection, and Hypersensitivity Reactions

  2021cites this paper
• Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies

  2020cites this paper
• Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.

  2020cites this paper
• Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles

  2020cites this paper
• Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles

  2020cites this paper
• Complex Metal Ions: Neuropsychiatric and Imaging Features.

  2020cites this paper
• Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report and a comprehensive evidence-based review

  2019cites this paper
• Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.

  2019cites this paper
• Update on multiparametric MRI of urinary bladder cancer

  2018cites this paper
• Gadolinium use for interventional pain procedures: where we are and where we are heading

  2018cites this paper
• Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease

  2018cites this paper
• Gadopentatic acid affects in vitro proliferation and doxorubicin response in human breast adenocarcinoma cells

  2018cites this paper
• Gadolinium-Based Contrast Agent-Related Toxicities

  2018cites this paper
• Caution in Using Gadolinium-Based Contrast Agents in Interventional Pain Procedures.

  2018cites this paper
• Safety of Gadolinium Administration in Children.

  2018cites this paper
• [Ablative therapy in kidney cancer: Indications].

  2017cites this paper
• Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias

  2017cites this paper
• Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.

  2017cites this paper
• The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.

  2017cites this paper
• Accumulation and Toxicity: An Update Gadolinium-Based Contrast Agent

  2016cites this paper
• Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update

  2016cites this paper
• Impact of Impaired Renal Function on Gadolinium Retention After Administration of Gadolinium-Based Contrast Agents in a Mouse Model

  2016cites this paper
• Rare Earth Element Toxicity to Marine and Freshwater Algae

  2016cites this paper
• Synthesis of pH-responsive polymers via raft polymerization and their use for preparation of pH-responsive MRI contrast agents

  2015cites this paper
• Health effects and toxicity mechanisms of rare earth elements-Knowledge gaps and research prospects.

  2015cites this paper
• An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis

  2015cites this paper
• Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium‐based contrast agents

  2015cites this paper
• Nephrogenic Systemic Fibrosis Implications for the Pathogenesis of Proinflammatory Phenotype and Macrophages: Establishment of a TLR 4 and TLR 7 in Normal Human Gadolinium Compounds Signaling through

  2015cites this paper
• Contrast Agents in Radiology

  2014cites this paper
• The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update

  2014influential citation
• Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation

  2014cites this paper
• Induction of a type I interferon signature in normal human monocytes by gadolinium‐based contrast agents: comparison of linear and macrocyclic agents

  2014cites this paper
• Side Effects and Complications of Magnetic Resonance Contrast Media

  2012cites this paper
• Sheffield 2nd International Workshop on experimental studies of nephrogenic systemic fibrosis, 15th June 2012, Sheffield, UK

  2012cites this paper
• Gadolinio y fibrosis sistémica nefrogénica

  2012cites this paper
• Nephrogenic Systemic Fibrosis

  2012cites this paper
• Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis

  2012cites this paper
• Integrin-mediated signaling contributes to gadolinium-containing-particle-promoted cell survival and G1 to S phase cell cycle transition by enhancing focal adhesion formation

  2012cites this paper
• Stimulation of Fibroblast Proliferation by Insoluble Gadolinium Salts

  2012cites this paper
• Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance

  2012cites this paper
• Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging

  2012cites this paper
• Growth Control in Colon Epithelial Cells: Gadolinium Enhances Calcium-Mediated Growth Regulation

  2012cites this paper
• Gadolinium Compounds Signaling through TLR 4 and TLR 7 in Normal Human Macrophages: Establishment of a Proinflammatory Phenotype and Implications for the Pathogenesis of Nephrogenic Systemic Fibrosis

  2012cites this paper
• Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?

  2012cites this paper
• Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

  2012cites this paper
• Development and haematotoxicological evaluation of doped hydroxyapatite based multimodal nanocontrast agent for near-infrared, magnetic resonance and X-ray contrast imaging

  2012influential citation
• Magnetic Resonance Evaluation of Renal Artery Stenosis in a Swine Model: Performance of Low-Dose Gadobutrol Versus Gadoterate Meglumine in Comparison With Digital Subtraction Intra-Arterial Catheter Angiography

  2012cites this paper
• Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden

  2012cites this paper
• Understanding Nephrogenic Systemic Fibrosis

  2012cites this paper
• Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.

  2011cites this paper
• In the assessment of supratentorial glioma grade: the combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging.

  2011cites this paper
• Gadolinium Contrast Agent Associated Stimulation of Human Fibroblast Collagen Production

  2011influential citation
• Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.

  2011cites this paper
• Fibroblast Response to Lanthanoid Metal Ion Stimulation: Potential Contribution to Fibrotic Tissue Injury

  2011cites this paper
• Renal Imaging in Patients with Renal Impairment

  2011cites this paper
• Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level.

  2011cites this paper